Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial(s). ^[1]
• In adult patients with Multiple Myeloma (MM) undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT), 92.5% of those treated with motixafortide + G-Cerebrospinal Fluid (CSF) collected ≥6 x 10^6 CD34(+) cells kg(-1) within two apheresis procedures, compared to 26.2% in the placebo + G-CSF group (Overall Response (OR) 53.3, 95% Confidence Interval (CI) 14.12-201.33, P < 0.0001). 3. 88.8% of patients in the motixafortide + G-CSF group achieved the target CD34(+) cell collection in one apheresis procedure, compared to 9.5% in the placebo + G-CSF group (OR 118.0, 95% CI 25.36-549.35, P < 0.0001).
• The most common treatment-emergent adverse events in adult patients with Multiple Myeloma (MM) undergoing ASCT were injection site reactions, including pain (50%), erythema (27.5%), and pruritus (21.3%), all of which were transient and graded as 1/2 in severity.
• No significant safety concerns or adverse effects were reported beyond mild injection site reactions.
• The study included adult patients with Multiple Myeloma (MM) undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT), with no significant differences in effectiveness or safety among different subgroups reported.